Liposomal Bupivacaine
Cross-source consensus on Liposomal Bupivacaine from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Benefits
Evidence quality
Highlighted claims
- Liposomal bupivacaine is an ultra-long-acting local anesthetic based on DepoFoam technology. — Liposomal bupivacaine versus standard ropivacaine for pain control in adults receiving continuous supraclavicular brachial plexus blocks for open elbow arthrolysis: study protocol for a randomised controlled non-inferiority clinical trial
- Liposomal bupivacaine forms a local depot that slows bupivacaine release. — Liposomal bupivacaine versus standard ropivacaine for pain control in adults receiving continuous supraclavicular brachial plexus blocks for open elbow arthrolysis: study protocol for a randomised controlled non-inferiority clinical trial
- Evidence specific to open elbow arthrolysis remains scarce. — Liposomal bupivacaine versus standard ropivacaine for pain control in adults receiving continuous supraclavicular brachial plexus blocks for open elbow arthrolysis: study protocol for a randomised controlled non-inferiority clinical trial
- A single postoperative dose of liposomal bupivacaine can provide analgesia for up to 72 hours. — Liposomal bupivacaine versus standard ropivacaine for pain control in adults receiving continuous supraclavicular brachial plexus blocks for open elbow arthrolysis: study protocol for a randomised controlled non-inferiority clinical trial
- Prior studies in distal radius fixation, shoulder surgery, and shoulder arthroplasty support the rationale for testing liposomal bupivacaine in this setting. — Liposomal bupivacaine versus standard ropivacaine for pain control in adults receiving continuous supraclavicular brachial plexus blocks for open elbow arthrolysis: study protocol for a randomised controlled non-inferiority clinical trial